Barbara Peil

Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial

Muhammad Shahzeb Khan, Stefan D. Anker, Gerasimos S Filippatos, João Pedro Ferreira et autres

BACKGROUND: The presence of ischemic heart disease impacts prognosis in patients affected by heart failure and reduced ejection fraction (HFrEF). It is not well known how the extent of vascular disease impacts prognoses and responses to therapy in this setting. METHODS: vs …

us, de, gr, fr, pt, gb, in, pl, ca, se (code pays fourni par la source)

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

Madeline Lee Pe, Ahu Alanya, Ragnhild Sørum Falk, Cecilie Delphin Amdal et autres

be, no, us, nl, at, gb, de (code pays fourni par la source)

Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity

Susanna Bianzano, Matias Nordaby, Leona Plum‐Mörschel, Barbara Peil et autres

AIMS: To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity. MATERIALS AND METHODS: . RESULTS: In total, …

de (code pays fourni par la source)

Author response for "Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity"

Susanna Bianzano, Sam Rose, Matias Nordaby, Leona Plum‐Mörschel et autres

Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced

Stefan D. Anker, Muhammad Shahzeb Khan, Javed Butler, Anne Pernille Ofstad et autres

AIMS: Baseline body mass index (BMI) and weight loss promoted by sodium-glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR-Reduced population treated with empagliflozin versus placebo the relationship between …

pl, de, us, no, gb, gr, fr, pt (code pays fourni par la source)

Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF

Javed Butler, Muhammad Shahzeb Khan, JoAnn M. Lindenfeld, William T. Abraham et autres

BACKGROUND: Differences in clinically important thresholds in patient-reported outcomes measures such as the Kansas City Cardiomyopathy Questionnaire (KCCQ) remain less well-established in patients with heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: The purpose …

us, se, br, de, gr, pl (code pays fourni par la source)

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials

Stefan D. Anker, Piotr P. Ponikowski, Christoph Wanner, Egon Pfarr et autres

de, pl, Égypte, cn, us, fr, au (code pays fourni par la source)

Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Emperial Trials

Stefan D. Anker, Piotr P. Ponikowski, Christoph Wanner, Egon Pfarr et autres

de, pl, us (code pays fourni par la source)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Javed Butler, Stefan D. Anker, Gerasimos S Filippatos, Muhammad Shahzeb Khan et autres

AIMS: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. METHODS AND RESULTS: Health …

us, de, gr, fr, gb, ca, sg, pl, se (code pays fourni par la source)

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

William T. Abraham, JoAnn M. Lindenfeld, Piotr P. Ponikowski, Piergiuseppe Agostoni et autres

AIMS: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with …

us, pl, it, gr, cy, se, no, ca, au, es, de, pt (code pays fourni par la source)

Efficacy and Safety of Diclofenac + Capsaicin Gel in Patients with Acute Back/Neck Pain: A Multicenter Randomized Controlled Study

Hans‐Georg Predel, Caty Ebel‐Bitoun, Barbara Peil, Thomas W. Weiser et autres

Back and neck pain are common musculoskeletal disorders. Topical non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used to reduce pain and inflammation with fewer systemic side effects and drug interactions compared with oral NSAIDs. This study assessed efficacy and tolerability of a topical …

de, fr (code pays fourni par la source)

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

Heinz‐Josef Lenz, Guillem Argilés, Takayuki Yoshino, Sara Lonardi et autres

INTRODUCTION: We used European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) data from the LUME-Colon 1 study to illustrate different methods of statistical analysis for health-related quality of life (HRQoL), and compared the results. PATIENTS AND …

us, es, jp, it, de, be (code pays fourni par la source)